Cannabidiol trial shows reduction in seizures for children with Dravet syndrome

30 May 2017, 12:58 p.m.

A woman is stood smiling at the camera in a red jacket and shelves of dossiers behind her.

A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.

The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.

In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.

The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.

Read the press release.

Landmark decision to screen for spinal muscular atrophy at birth

Great Ormond Street Hospital (GOSH) is delighted at the announcement that newborn babies in England will be offered screening for spinal muscular atrophy (SMA) through the newborn blood spot, or "heel prick", test programme.

Building the next generation of paediatric research leaders

From early career clinicians to emerging scientists, the NIHR GOSH Biomedical Research Centre (BRC)’s Academic Training Weekend is shaping the future of paediatric research - bringing together talent, expertise and ambition from across the UK.

A catalyst to unlock the next generation of research leaders

The NIHR GOSH Biomedical Research Centre (BRC) Fellowships are transforming early-career researchers into independent leaders - driving innovation, attracting millions in funding and shaping the future of paediatric science.

Shaping better research from the start

At GOSH, patient and public involvement is helping researchers to ask the right question, right from the start.